#Vray ipo full#
#Vray ipo software#

In 2013, VRAY executed new sales contracts with a total value of $17.4 million, and in 2014 executed new sales contracts with a total value of $37.6 million.ДЄt December 31, 2014, VRAY had 10 signed sales contracts for MRIdian systems in backlog with a total value of $54.7 million, of which VRAY expects to recognize approximately 40% to 60% as revenue in 2015 representing four to six MRIdian systems.Д¬an be used for different types of cancer VRAY believes this leads to improved patient outcomes and reduced side effects from off-target radiation delivery.

These capabilities allow MRIdian to accurately deliver radiation to the tumor while reducing the amount delivered to healthy tissue, as compared to other radiation therapy treatments today.

#Vray ipo software#

MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the location and shape of soft-tissue tumors while radiation is delivered. MRI is a broadly used imaging tool that has the ability to differentiate between types of soft tissue clearly, unlike X-ray or computed tomography, or CT, which are the most commonly used imaging technologies in radiation therapy today. P/E of -5.5, indicates high cash burn rate relative to market cap If 50% of backlog converted to sales, '15 sales will be up 430% MRIdian is a new technology in the radiation therapy systems sector.Дec '14 backlog is $55mm, 8.6 times 2014 salesД¤0-60% of backlog expected to be converted to 2015 sales VRAY designs, manufactures and markets MRIdian, the first and only MRI-guided radiation therapy system to image and treat cancer patients simultaneously.

#Vray ipo full#

The full IPO calendar is available at IPOpremium. P/E of -5.5, indicates high cash burn rate relative to market cap.Д«ased in Oakwood Village, Ohio, ViewRay Inc (NASDAQ: VRAY) scheduled a $52 million IPO on Nasdaq with a market capitalization of $189 million at a price range midpoint of $13 for Thursday, March 26, 2015.

If 50% of backlog converted to sales, '15 sales will be up 430%. Designs, manufactures and markets MRIdian, the first and only MRI-guided radiation therapy system to image and treat cancer patients simultaneously.